CS Paper Radar

The Diagnosis a Reporter Leaves Unspoken: Surfacing Frozen Tumor Features for Brain-Tumor MRI Reporting

Khawaja Murad ul Hassan, Ruqiyya Adil, Adil Qayyum, Rida Hassan, Asad Mansoor Khan, Muhammad Usman Akram, Mehran Ebrahimi

cs.CV ·submitted 2026-09-02 10:29 UTC · v1
published

Abstract

A capable brain-MRI report generator can still be, in effect, diagnostically silent. When a multi-chain chain-of-thought (CoT) reporter built on a medical Mistral-7B backbone is evaluated on held-out cohorts, it names most meningiomas and almost all metastases "glioma" (diagnosis recall 0.44/0.07). Yet the answer is not absent from the model: a supervised linear probe applied to its frozen segmentation features recovers the three tumour cohorts at 0.82 macro-F$_1$ (5-fold cross-validation; chance $\approx$0.33). We introduce NeuroFusion, an assistive reporter that surfaces this latent signal rather than overriding it: discriminative field-classifier heads over per-lesion features condition a fast, single-pass draft-then-review decoder on their committed outputs. Built on the identical Mistral backbone, this restores the diagnosis (meningioma 0.92, metastasis 0.75) and wins 8 of 9 prose-content comparisons across three held-out cohorts (RaTEScore, RadGraph-F$_1$, GREEN; Holm-corrected paired BCa), with no significant loss on the ninth, at 5-6x lower latency ($\approx$80 vs. 457 s/case). A controlled negative result sharpens the mechanism: a learned diagnosis pin that overrides the decoder instead of merely informing it collapses out-of-distribution metastasis recall to 0.03. Grammar-constrained decoding keeps 92.3% of records schema-valid, making every sentence entailment-checkable (7.5% contradicted vs. 36.8% for the direct baseline). In a blinded nine-case pilot, two board-certified neurologists independently rated NeuroFusion highest in every tumour type, the only system with zero critical errors, and gave it the top-rated sign-off in eight of nine cases (six outright, two ties).

Comment
10 pages, 2 figures, 3 tables. Accepted at MLCN 2026, a workshop held in conjunction with MICCAI 2026; to appear in Springer LNCS

Closest papers

Nearest neighbours by meaning across the whole index.

Evidence-Bound Reasoning: Neuro-Semantic Verification of Biomedical AI in Glioblastoma Radiogenomics

cs.CL ·2026-10-06 ·Mariya Miteva, Maria Nisheva-Pavlova
benchmark similarity 0.68
Abstract · 15 pages, 4 figures, 4 tables. Preprint

Background: Biomedical AI can generate plausible explanations without reliably verifying whether each statement is supported by patient-specific evidence. We developed a neuro-semantic verification framework that converts radiomic measurements into addressable evidence records and machine-checkable claims. Methods: UPenn-GBM radiomics were aligned with de novo CaPTk extraction from standardized MRI and expert-validated segmentations in an independent multicenter cohort. The shared space comprised 1,728 features from T1, T1GD, T2, and FLAIR MRI across three tumor regions. Reference-defined semantic states were derived from 611 UPenn cases. We evaluated cross-cohort transportability, model-linked provenance, deterministic verification, controlled predictive degradation, and an LLM claim-extraction pilot; MGMT prediction served only as a transport stress test. Results: Median semantic-state agreement was 0.786 (weighted kappa 0.709), ranging from 0.918 for morphologic to 0.252 for intensity features. The external evidence ledger contained 1,655 model-linked records for 331 patients. The verifier achieved 100% exact-set accuracy in a 6,620-claim corruption benchmark. In a 24-case pilot, GPT-5.6 Sol reproduced 72/72 prespecified atomic claims, and the frozen verifier recovered 24/24 expected conditions. During controlled degradation, ROC AUC declined from 0.899 to 0.500 while verification accuracy remained 1.000. External MGMT discrimination was weak (ROC AUC 0.543). Conclusions: Verifiability can be engineered and evaluated independently of predictive performance. LLMs may structure explanations, while final evidence-consistency checking remains deterministic.

0.23

Explainable and CPU-Efficient Brain Tumor Classification from MRI Using Two-Phase EfficientNetB3 Fine-Tuning

cs.CV ·2026-11-18 ·Deepro Das, Saad Kabir Uddin, Mohammad Alauddin, Bornali Sarker, Thasnim Akhter
similarity 0.68
Abstract · 6 pages, 5 figures, 6 tables

Brain tumors are among the most lethal neurological disorders, with over 308,000 new diagnoses annually worldwide. Accurate classification of tumor type from Magnetic Resonance Imaging (MRI) scans is critical for treatment planning; however, manual radiological interpretation is time-consuming and prone to inter-observer variability. This paper proposes an automated deep learning pipeline for four-class brain MRI classification (glioma, meningioma, no tumor, and pituitary tumor) using EfficientNetB3 transfer learning with a custom classification head. A two-phase training strategy is adopted: Phase 1 trains the head with a frozen backbone (best validation accuracy: 92.77%), and Phase 2 selectively fine-tunes the top 37 layers at a 100x reduced learning rate (best validation accuracy: 94.91%). On an independent balanced test set of 1,600 MRI images, the system achieves 90.62% overall accuracy and a macro-average AUC of 0.9854. Gradient-weighted Class Activation Mapping (Grad-CAM) is integrated for class-discriminative visual explainability. The proposed system simultaneously addresses three dimensions absent in prior work: high accuracy, CPU-only computational efficiency, and clinical interpretability.

0.14

A Trustworthy Clinical Decision Support Framework for Brain Tumor MRI Classification: Integrating Attention-Guided Learning, Explainable AI, and Out-of-Distribution Validation

cs.CV cs.AIcs.LG ·2026-10-06 ·Arjun Kumar Gupta, Harminder Pal Monga
publishedbenchmark similarity 0.67
Abstract · Accepted for presentation at the IC3AI-2026 IEEE conference in Dec 2026. It has been accepted/selected but is not yet published. 6 pages, 4 …

Deep learning models for brain tumor diagnosis need to do more than achieve high classification accuracy. For practical use, they should also provide understandable predictions, recognize unsuitable inputs, and work within a usable clinical system. This paper presents a framework for classifying brain MRI into four categories: glioma, meningioma, pituitary tumor, and no tumor. The model uses InceptionResNetV2 with a Convolutional Block Attention Module (CBAM), while Grad-CAM provides visual explanations of its predictions. A two-stage out-of-distribution (OOD) mechanism screens unsuitable inputs using an initial grayscale check followed by Mahalanobis distance, softmax confidence, and predictive entropy. These components are brought together in NeuroScan AI, a real-time web application. Evaluated on a Mendeley brain tumor MRI dataset of 12,064 images, the framework achieved 98.70% validation accuracy, 96.73% test accuracy, and a macro-average AUC of 0.9965. The OOD pipeline achieved 99% detection accuracy on a preliminary 100-image benchmark. Grad-CAM visualizations showed qualitative correspondence with clinically established tumor locations across all four classes. Overall, the work brings classification, explainability, input validation, and deployment into one framework, while recognizing that broader clinical and OOD validation is still required.

0.25

A Vision-Language Foundation Model for Precise and Comprehensive Brain Tumor Diagnosis from Preoperative Multimodal Data

cs.CV cs.AI ·2026-09-15 ·Yinong Wang, Jianwen Chen, Zhou Chen, Shuwen Kuang, Haoning Jiang +26 more
code/data similarity 0.65
Abstract · 94 pages, 22 Figures, supplement files, Project page link: https://hku-healthai.github.io/brainvlm_project.github.io/

We developed BrainVLM to classify all 12 World Health Organization (WHO) 2021 brain tumor types. BrainVLM integrates an uncertainty quantification strategy to indicate prediction reliability and a module for generating radiology reports to elucidate the clinical rationale. BrainVLM was trained on multi-modal data (MRI scans, demographics, and radiology reports) from 40,043 individuals. It was validated on 5,211 patients with pathologically confirmed brain tumors, including 3,877 held-out patients from the primary hospital and 1,334 patients from 11 independent hospitals. We further conducted two proof-of-concept studies to validate its clinical utility in AI-clinician workflows: 1) a blinded multireader study where 12 neuroradiologists across varying experience levels interpreted 248 retrospective cases with or without AI assistance, and 2) a real-world prospective study in which 1,009 patients were independently and blindly assessed by BrainVLM and radiologists before surgery. Additionally, we demonstrated BrainVLM's utility in preoperative molecular subgroup prediction for adult-type diffuse gliomas, using a multi-center cohort of 632 patients. In primary evaluation, BrainVLM achieved an area under the curve (macro-AUC) of 0.85 (95% CI: 0.84-0.86), and an F1 score of 0.82 (95% CI: 0.81-0.83), surpassing neuroradiologists (F1 = 0.80 (95% CI: 0.79-0.81)). In external validation across 11 centers, BrainVLM achieved an AUC = 0.80 (95% CI: 0.79-0.82) and F1 = 0.75 (95% CI: 0.73-0.78), compared with F1 = 0.71 (95% CI: 0.69-0.73) for neuroradiologists. In prospective real-world evaluation, BrainVLM maintained performance comparable to neuroradiologists. The BrainVLM project page is available at https://hku-healthai.github.io/brainvlm_project.github.io/.

0.35

Brain Metastases Segmentation for BraTS 2026 Task 1: A Multi-Architecture Comparison

cs.CV ·2026-09-21 ·Mahdi Islam, Musarrat Tabassum
publishedcode/data similarity 0.65
Abstract · 10 pages, 1 figure. Accepted as a poster at the BraTS 2026 Challenge, MICCAI 2026. Code: https://github.com/mahdiislam79/BraTS_METS_2026

Brain metastases are the most common intracranial malignancy, occurring in roughly 30% of patients with primary solid tumors and carrying a median survival near 5.9 months. Automated segmentation is critical for treatment planning and volumetric monitoring, but metastases are frequently small, numerous, and heterogeneous in size within a single patient. We compare a plain nnU-Net baseline, a Residual Encoder Large (ResEncL) variant, region-based training, and a Primus transformer model for BraTS-METS 2026 Task 1, using patient-grouped cross-validation to prevent leakage from the longitudinal UCSD subset. Primus (label-based) is our strongest individual model by aggregate DSC/NSD, achieving 0.710/0.761 (ET), 0.742/0.785 (TC), 0.683/0.689 (WT), and 0.531/0.436 (RC). ResEncL trails Primus on aggregate DSC/NSD but achieves substantially higher lesion-wise F1 (e.g. ET: 0.452 vs. 0.052); a probability-averaging ensemble of the two only partially preserves ResEncL's F1 advantage (ET lesion-wise F1: 0.064). We further report three postprocessing and label-reconstruction pitfalls we believe generalize beyond this challenge. Code is available at https://github.com/mahdiislam79/BraTS_METS_2026.

0.31

VGG16-MCA UNet: Whole-Tumor Segmentation in 2D FLAIR MRI with Decoder-Side Channel Attention

eess.IV cs.CV ·2026-09-20 ·Shubham Gajjar, Deep Joshi, Avi Poptani, Vishal Barot
benchmarktheorycode/data similarity 0.65
Abstract · 22 pages, 7 figures, 4 tables. Code and data splits: https://github.com/ShubhamGajjar/vgg16-mca-unet

Automated brain tumor segmentation supports diagnosis, treatment planning, and monitoring of disease progression, but building models that generalize across heterogeneous tumors and limited annotated data remains difficult. We present VGG16-MCA UNet, a hybrid architecture pairing an ImageNet-pretrained VGG16 encoder with a decoder in which a Multi-Channel Attention (MCA) module recalibrates features after each skip-connection fusion, trained with the Focal Tversky loss to counter severe foreground-background imbalance. We evaluate the model as a 2D, FLAIR-only, whole-tumor segmenter on tumor-positive slices from two public datasets: the BraTS 2020 benchmark and the LGG MRI Segmentation dataset. Using 5-fold cross-validation and a single network formed by averaging the weights of the five fold models, the method attains an aggregate pixel-level Dice (F1) of 95.10% on our held-out BraTS 2020 split and 88.32% on LGG. These scores are computed over all test pixels pooled into a single confusion matrix rather than averaged per case, and are therefore not directly comparable to the per-case mean Dice used in the BraTS challenge protocol. All partitions were drawn over individual slices rather than over patients, so every patient contributes slices to both training and test; the figures above therefore measure interpolation within known patients and should be read as an upper bound rather than as generalization to new ones. The model segments a 256x256 slice in 66.32 ms on a single 6 GB NVIDIA RTX 2060, approximately 8 ms more than an equivalent VGG16-UNet without MCA. We release the split records and report the protocol in full, with the aim of providing a precisely specified and reproducible 2D FLAIR baseline.

0.23

Pre- and Post-Treatment Brain Metastases Segmentation Using nnU-Net with Post-Processing for BraTS 2026

cs.CV ·2026-09-10 ·Haobin Liu, Xin Wang
publishedbenchmarkcode/data similarity 0.65
Abstract · Accepted to MICCAI 2026 Challenge BraTS-METS

Brain metastases exhibit high inter-lesion variability in size, enhancement pattern, and post-treatment appearance, making volumetric segmentation of both pre- and post-treatment cases the central challenge of the BraTS 2026 Task 1 (Brain Metastases). We build a pragmatic pipeline on a 5-fold nnU-Net ResEnc-L ensemble, in which each fold is trained independently for 1,000 epochs with the standard Dice + cross-entropy loss on 1,296 four-modality training cases. This ensemble is followed by a rule-based post-processing cascade tuned for the lesion-wise Dice similarity coefficient (LW-DSC), a detection-oriented metric that behaves very differently from the traditional global Dice. The final pipeline reaches an LW-DSC of 0.733 / 0.751 / 0.713 / 0.549 on the enhancing tumour (ET), tumour core (TC), whole tumour (WT), and resection cavity (RC) sub-regions on the official validation leaderboard. Rather than trusting these leaderboard gains, we audit every post-processing stage with a five-fold out-of-fold (OOF) analysis with no model-training leakage over all 1,296 training cases, scored with the official BraTS evaluation code (BraTS_evaluation): it confirms two stages as robust, per-fold-consistent improvements while the third improves only the leaderboard and does not reproduce out-of-fold. We further provide a mechanistic analysis of the LW-DSC metric that explains why recall-recovering post-processing carries low risk whereas component deletion does not, and we report thirteen negative results spanning loss engineering, alternative backbones, and inference-time settings, several of which run counter to widely held intuitions. Source code is released under Apache-2.0 at https://github.com/hornbeamliu/brats2026-met.

0.48

The Federated Tumor Segmentation and Classification (FeTS++) Challenge

cs.CV ·2026-10-13 ·Wenyi Tang, Carla Pitarch-Abaigar, Siddhesh Thakur, Verena Chung, Konstantinos Koukoutegos +3 more
similarity 0.65
Abstract

International challenges have become the standard for developing and benchmarking biomedical image analysis methods using centralized multi-institutional data. Federated learning (FL) describes a paradigm-shift on multi-institutional collaborations, where models are trained across institutions while their data are always retained locally. The Federated Tumor Segmentation (FeTS) challenge, first held in 2021, was the first challenge dedicated to FL in medical imaging and editions in 2022 and 2024 pushed the frontiers of real-world method validation. FeTS++ 2027 returns after a two-year gap with a substantially larger and more diverse cohort, and with the two "pluses" that name the challenge: an official classification task alongside segmentation, and a move of the infrastructure to NVIDIA FLARE (NVFlare). Built on the clinically acquired, multi-institutional multi-parametric MRI data of the BraTS 2025 Lighthouse challenge, FeTS++ spans gliomas and meningiomas across patient cohorts from institutions in North America, Europe, Asia, and Africa, and focuses on ranking submitted methodological approaches according to their model utility and an efficiency-aware score. Task 1 asks participants to find the best strategy for aggregating knowledge from per-institution segmentation models, while Task 2 asks them to distinguish glioma from meningioma under the same federated protocol, in which the entity label is heavily confounded with the site of origin.

0.17